JAVELIN Merkel 200: avelumab for metastatic Merkel cell carcinoma
Patients with metastatic Merkel cell carcinoma (MCC) that does not respond to chemotherapy have a very poor survival rate after 1-2 years, representing a great unmet need. Here, Paul Nghiem, MD, PhD, ...
Author: VJOncology
Added: 08/13/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts